联合开发心脏药物III期试验未达主要终点，阿斯利康与Ionis股价暴跌

智通财经07-09

7月9日，阿斯利康与 Ionis Pharmaceuticals, Inc联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。此次代号为CARDIO-TTRansform的III期试验评估的是Wainua(eplontersen)在转甲状腺素蛋白介导的淀粉样变性心肌病(ATTR-CM)患者中的疗效。结果显示，与安慰剂相比，该药在...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2650929828?lang=zh_CN&edition=full","thumbnail":"https://community-static.tradeup.com/news/56ac818c9a46212bd08488d4935a4dad","is_english":false,"pubTime":"2026-07-09 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650929828","market":"us","top_or_hot":-1,"title":"联合开发心脏药物III期试验未达主要终点，阿斯利康与Ionis股价暴跌","media":"智通财经","content":"<div>\n<p>7月9日，阿斯利康与 Ionis Pharmaceuticals, Inc联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。此次代号为CARDIO-TTRansform的III期试验评估的是Wainua(eplontersen)在转甲状腺素蛋白介导的淀粉样变性心肌病(ATTR-CM)患者中的疗效。结果显示，与安慰剂相比，该药在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1465485.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>联合开发心脏药物III期试验未达主要终点，阿斯利康与Ionis股价暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n联合开发心脏药物III期试验未达主要终点，阿斯利康与Ionis股价暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-09 19:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1465485.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月9日，阿斯利康与 Ionis Pharmaceuticals, Inc联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。此次代号为CARDIO-TTRansform的III期试验评估的是Wainua(eplontersen)在转甲状腺素蛋白介导的淀粉样变性心肌病(ATTR-CM)患者中的疗效。结果显示，与安慰剂相比，该药在...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1465485.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0058720904.USD","symbol_name":"联博国际健康护理基金A","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1465485.html","article_id":"2650929828","we_media_id":null,"thumbnails":["https://community-static.tradeup.com/news/56ac818c9a46212bd08488d4935a4dad"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650929828","pubTimestamp":1783598269,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"7月9日，阿斯利康与IONS联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0058720904.USD":"联博国际健康护理基金A","III":"信息服务","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","BK4588":"碎股","BK4568":"美国抗疫概念","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AZN":"阿斯利康","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4134":"信息科技咨询与其它服务","BK4007":"制药","IONS":"Ionis Pharmaceuticals, Inc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AZNH":"ASTRAZENECA PLC ADRhedged","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4139":"生物科技","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC"},"translate_title":"Jointly Developed Heart Drug Phase III Trial Misses Primary Endpoint AstraZeneca (AZN.US) and Ionis (IONS.US) Shares Plunge","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/8f06b28875b8147cc9e8c6a818a0a161","symbols_score_info":{"IONS":2.1,"AZNH":0.6,"AZN":2.1,"III":1.5},"content_text":"7月9日，阿斯利康与 Ionis Pharmaceuticals, Inc联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，Ionis股价盘前下跌超20%，阿斯利康盘前跌超8%。此次代号为CARDIO-TTRansform的III期试验评估的是Wainua(eplontersen)在转甲状腺素蛋白介导的淀粉样变性心肌病(ATTR-CM)患者中的疗效。结果显示，与安慰剂相比，该药在140周内未能达到复合终点——即心血管死亡率与复发性心血管临床事件——的主要疗效指标。Wainua是一种每月给药一次的RNA靶向沉默剂，在美国可由患者通过自动注射笔自行给药，或由医护人员以预充式注射器方式给药。根据合作协议，阿斯利康与Ionis在美国市场共同负责Wainua的开发和商业化;美国以外市场，阿斯利康则拥有全球独家开发和商业化权利。两家公司表示，将对完整数据集进行进一步分析，以深入理解试验结果，并计划在2026年8月召开的欧洲心脏病学会(ESC)年会上向学术界公布相关数据。花旗此前已将Wainua在ATTR-CM适应症的峰值销售额预测为约62亿美元，并给予59%的成功概率。部分分析师此前预计该药可能带来最多约20亿美元的销售机会。此次失败意味着这一潜在重磅药物从阿斯利康的心血管管线中移除。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650929828","isCrawlerRequest":true}